Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by MustangSalleyon Jun 01, 2022 11:58am
178 Views
Post# 34723534

RE:ViaCyte

RE:ViaCyte
BioTeck wrote: Just when we thought they were teets up, they may beat us at getting stem cells in a device into a body. Whether it works or not is another story but A for effort. Partnered with CRISPR for immuno suppression gene editing which sounds like won't be in the clinic this year. https://www.med.ubc.ca/news/b-c-researchers-launching-clinical-trial-for-first-genetically-engineered-stem-cell-based-therapy-for-type-1-diabetes/


Viacycte lol...... it is in Canada with limited money . Funny how Vertex and Viacycte are doing trials in Canada ... it's like being on the Venture exchange .

Fda is the gold standard.  To get any recognition by pharma and worldwide acceptance Fda and US trials are crtitical .

Viacytes original trial did not fair well with limited c peptide production . So the fact the competition is starting to use devices now validates Sva scientific program.  Note there is no major funding form any pharma's for this $ 1 million Canadian trial at UBC.

Hopefully Sva can announce Thyroid trial at UBC soon.

MS

<< Previous
Bullboard Posts
Next >>